Stocks Health care TRAX

NASDAQ · Health care

First Tracks Biotherapeutics, Inc. (TRAX)

At September 30, 2026 it held $155.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.

Watch TRAX in 60 seconds

Follow TRAX

Free, no password. An email when TRAX files with the SEC.

Key facts about First Tracks Biotherapeutics, Inc.

Net worth

First Tracks Biotherapeutics, Inc. has a market value (market cap) of $1.8B at the latest share price, and shareholders' equity of $151M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR

Next earnings report

First Tracks Biotherapeutics, Inc.'s next report is expected around January 29, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

What First Tracks Biotherapeutics, Inc. does

First Tracks Biotherapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TRAX.

Earnings: every quarter and the next report date

Latest SEC filings

What First Tracks Biotherapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. November 6, 2026
   Passive stake changed SCHEDULE 13G/A
2. November 3, 2026
   Quarterly report 10-Q · period to September 30, 2026Diluted EPS -$0.88 versus -$1.50.
3. November 3, 2026
   Quarterly results 8-K
4. October 27, 2026
   Passive stake changed SCHEDULE 13G/A
5. October 26, 2026
   IPO registration S-1
6. October 20, 2026
   Material agreement 8-K
7. October 15, 2026
   Material agreement 8-K
8. October 13, 2026
   Investor disclosure 8-K
9. August 14, 2026
   Passive stake (5% or more) SCHEDULE 13G
10. August 14, 2026
    Passive stake (5% or more) SCHEDULE 13G

Recent insider filings (Forms 3, 4 and 144): 10, the latest on November 3, 2026. Insider transactions on SEC

Insider trades

What the people running First Tracks Biotherapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $1.8M worth of shares in the last 90 days and bought none on the open market.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns TRAX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 149 managers reported a position.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

7 insiders reported holding 3,291,975 shares in total, about $168.9M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about TRAX

What does First Tracks Biotherapeutics, Inc. do?

First Tracks Biotherapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as TRAX. Its shares trade on NASDAQ under the ticker TRAX.

What is First Tracks Biotherapeutics, Inc.'s net worth?

First Tracks Biotherapeutics, Inc. has a market value (market cap) of $1.8B at the latest share price, and shareholders' equity of $151M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

When did First Tracks Biotherapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 6, 2026.

When is First Tracks Biotherapeutics, Inc.'s next earnings report?

First Tracks Biotherapeutics, Inc.'s next report is expected around January 29, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

Compare TRAX with

Compare TRAX with any company

Follow TRAX

Get an email when First Tracks Biotherapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow TRAX

Free, no password. An email when TRAX files with the SEC.

Where the numbers come from

Financial figures are the values First Tracks Biotherapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.